Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Pages for logged out editors learn more Contributions Talk CentralNotice Contents move to sidebar hide (Top) 1 Medical uses 2 Adverse effects 3 Mechanism of action 4 Biosynthetic pathway 5 History 6 Veterinary use 7 Research Toggle Research subsection 7.1 Animal model of depression and amotivation 7.2 Antibacterial effects 8 References 9 External links Toggle the table of contents Reserpine 33 languages العربية تۆرکجه Català Cymraeg Deutsch Ελληνικά Español فارسی Français Gaeilge 한국어 Հայերեն Hrvatski Bahasa Indonesia Italiano ქართული Қазақша Lietuvių Nederlands 日本語 Polski Português Română Русский Slovenčina Slovenščina Српски / srpski Srpskohrvatski / српскохрватски Suomi Svenska తెలుగు Українська 中文 Edit links Article Talk English Read Edit View history Tools Tools move to sidebar hide Actions Read Edit View history General What links here Related changes Upload file Permanent link Page information Cite this page Get shortened URL Download QR code Print/export Download as PDF Printable version In other projects Wikimedia Commons Wikidata item Appearance move to sidebar hide From Wikipedia, the free encyclopedia Drug used to treat high blood pressure Not to be confused with Reserpidine or Risperidone .

Pharmaceutical compound Reserpine Clinical data Trade names Serpasil, others AHFS / Drugs.com Consumer Drug Information MedlinePlus a601107 License data US FDA : Reserpine Pregnancy category C Routes of administration Oral ATC code C02AA02 ( WHO ) Legal status Legal status Rx-only (banned/discontinued in some countries) Pharmacokinetic data Bioavailability 50% Metabolism gut/liver Elimination half-life phase 1 = 4.5h, phase 2 = 271h, average = 33h Excretion 62% feces / 8% urine Identifiers IUPAC name methyl (3β,16β,17α,18β,20α)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate CAS Number 50-55-5 Y PubChem CID 5770 IUPHAR/BPS 4823 DrugBank DB00206 Y ChemSpider 5566 Y UNII 8B1QWR724A KEGG D00197 Y ChEBI CHEBI:28487 Y ChEMBL ChEMBL772 Y CompTox Dashboard ( EPA ) DTXSID7021237 ECHA InfoCard 100.000.044 Chemical and physical data Formula C 33 H 40 N 2 O 9 Molar mass 608.688 g·mol −1 3D model ( JSmol ) Interactive image SMILES [H][C@]26C[C@@H](OC(=O)c1cc(OC)c(OC)c(OC)c1)[C@H](OC)[C@@H](C(=O)OC)[C@@]2([H])C[C@]5([H])c4[nH]c3cc(OC)ccc3c4CCN5C6 InChI InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 Y Key:QEVHRUUCFGRFIF-MDEJGZGSSA-N Y (verify) Reserpine is a drug that is used for the treatment of high blood pressure , usually in combination with a thiazide diuretic or vasodilator.

[ 1 ] Large clinical trials have shown that combined treatment with reserpine plus a thiazide diuretic reduces mortality of people with hypertension. Although the use of reserpine as a solo drug has declined since it was first approved by the FDA in 1955, [ 2 ] the combined use of reserpine and a thiazide diuretic or vasodilator is still recommended in patients who do not achieve adequate lowering of blood pressure with first-line drug treatment alone.

[ 3 ] [ 4 ] [ 5 ] The reserpine- hydrochlorothiazide combo pill was the 17th most commonly prescribed of the 43 combination antihypertensive pills available in 2012.

[ 6 ] The antihypertensive actions of reserpine are largely due to its antinoradrenergic effects, which are a result of its ability to deplete catecholamines (among other monoamine neurotransmitters ) from peripheral sympathetic nerve endings. These substances are normally involved in controlling heart rate, force of cardiac contraction and peripheral vascular resistance.

[ 7 ] At doses of 0.05 to 0.2 mg per day, reserpine is well tolerated; [ 8 ] the most common adverse effect being nasal stuffiness.

Reserpine has also been used for relief of psychotic symptoms.

[ 9 ] A review found that in persons with schizophrenia, reserpine and chlorpromazine had similar rates of adverse effects, but that reserpine was less effective than chlorpromazine for improving a person's global state.

[ 10 ] Medical uses [ edit ] Reserpine is recommended as an alternative drug for treating hypertension by the JNC 8.

[ 11 ] A 2016 Cochrane review found reserpine to be as effective as other first-line antihypertensive drugs for lowering of blood pressure.

[ 12 ] The reserpine–thiazide diuretic combination is one of the few drug treatments shown to reduce mortality in randomized controlled trials : The Hypertension Detection and Follow-up Program, [ 13 ] the Veterans Administration Cooperative Study Group in Anti-hypertensive Agents, [ 14 ] and the Systolic Hypertension in the Elderly Program.

[ 15 ] Moreover, reserpine was included as a secondary antihypertensive option for patients who did not achieve blood pressure lowering targets in the ALLHAT study.

[ 16 ] It was previously used to treat symptoms of dyskinesia in patients with Huntington's disease , [ 17 ] but alternative medications are preferred today.

[ 18 ] The daily dose of reserpine in antihypertensive treatment is as low as 0.05 to 0.25 mg. The use of reserpine as an antipsychotic drug had been nearly completely abandoned, but more recently it made a comeback as adjunctive treatment, in combination with other antipsychotics, so that more refractory patients get dopamine blockade from the other antipsychotic, and dopamine depletion from reserpine. Doses for this kind of adjunctive goal can be kept low, resulting in better tolerability. Originally, doses of 0.5 mg to 40 mg daily were used to treat psychotic diseases.

Doses in excess of 3 mg daily often required use of an anticholinergic drug to combat excessive cholinergic activity in many parts of the body as well as parkinsonism. For adjunctive treatment, doses are typically kept at or below 0.25 mg twice a day.

Adverse effects [ edit ] At doses of less than 0.2 mg/day, reserpine has few adverse effects, the most common of which is nasal congestion.

[ 19 ] Reserpine can cause: nasal congestion, nausea, vomiting, weight gain, gastric intolerance, gastric ulceration (due to increased cholinergic activity in gastric tissue and impaired mucosal quality), stomach cramps and diarrhea. The drug causes hypotension and bradycardia and may worsen asthma. Congested nose and erectile dysfunction are other consequences of alpha-blockade.

[ 20 ] Central nervous system effects at higher doses (0.5 mg or higher) include drowsiness, dizziness, nightmares, Parkinsonism, general weakness and fatigue.

[ 21 ] High dose studies in rodents found reserpine to cause fibroadenoma of the breast and malignant tumors of the seminal vesicles among others. Early suggestions that reserpine causes breast cancer in women (risk approximately doubled) were not confirmed. It may also cause hyperprolactinemia .

[ 20 ] Reserpine passes into breast milk and is harmful to breast-fed infants, and should therefore be avoided during breastfeeding if possible.

[ 22 ] It may produce an excessive decline in blood pressure at doses needed for treatment of anxiety, depression, or psychosis.

[ 23 ] Mechanism of action [ edit ] See also: Monoamine-depleting agent Reserpine irreversibly blocks the H + -coupled vesicular monoamine transporters , VMAT1 and VMAT2 .

VMAT1 is mostly expressed in neuroendocrine cells. VMAT2 is mostly expressed in neurons. Thus, it is the blockade of neuronal VMAT2 by reserpine that inhibits uptake and reduces stores of the monoamine neurotransmitters norepinephrine , dopamine , serotonin and histamine in the synaptic vesicles of neurons.

[ 24 ] VMAT2 normally transports free intracellular norepinephrine, serotonin, and dopamine in the presynaptic nerve terminal into presynaptic vesicles for subsequent release into the synaptic cleft (" exocytosis "). Unprotected neurotransmitters are metabolized by MAO (as well as by COMT ), attached to the outer membrane of the mitochondria in the cytosol of the axon terminals, and consequently never excite the post-synaptic cell. Thus, reserpine increases removal of monoamine neurotransmitters from neurons, decreasing the size of the neurotransmitter pools, and thereby decreasing the amplitude of neurotransmitter release.

[ 25 ] As it may take the body days to weeks to replenish the depleted VMATs, reserpine's effects are long-lasting.

[ 26 ] Biosynthetic pathway [ edit ] Reserpine is one of dozens of indole alkaloids isolated from the plant Rauvolfia serpentina .

[ 27 ] In the Rauvolfia plant, tryptophan is the starting material in the biosynthetic pathway of reserpine, and is converted to tryptamine by tryptophan decarboxylase enzyme. Tryptamine is combined with secologanin in the presence of strictosidine synthetase enzyme and yields strictosidine. Various enzymatic conversion reactions lead to the synthesis of reserpine from strictosidine.

[ 28 ] History [ edit ] Reserpine was isolated in 1952 from the dried root of Rauvolfia serpentina (Indian snakeroot), [ 29 ] which had been known as Sarpagandha and had been used for centuries in India for the treatment of insanity, as well as fever and snakebites [ 30 ] — Mahatma Gandhi used it as a tranquilizer .

[ 31 ] It was first used in the United States by Robert Wallace Wilkins in 1950.  Its molecular structure was elucidated in 1953 and natural configuration published in 1955.

[ 32 ] It was introduced in 1954, two years after chlorpromazine .

[ 33 ] The first total synthesis was accomplished by R. B. Woodward in 1958.

[ 32 ] Reserpine was influential in promoting the thought of a biogenic amine hypothesis of depression.

[ 34 ] [ 35 ] Reserpine-induced depletion of monoamine neurotransmitters in the synapse allegedly caused depression and was cited as evidence that a "chemical imbalance", namely low levels of monoamine neurotransmitters, is what causes clinical depression in humans. A 2003 review showed barely any evidence that reserpine actually causes depression in either human patients or animal models.

[ 36 ] Notably, reserpine was the first compound ever to be shown to be an effective antidepressant in a randomized placebo-controlled trial.

[ 37 ] [ 38 ] A 2022 systematic review found that studies of the influence of reserpine on mood were highly inconsistent, with similar proportions of studies reporting depressogenic effects, no influence on mood, and antidepressant effects.

[ 39 ] The quality of evidence was limited, and only a subset of studies were randomized controlled trials .

[ 39 ] Although reserpine itself cannot provide good evidence for the monoamine hypothesis of depression, other lines of evidence support the idea that boosting serotonin or norepinephrine can effectively treat depression, as shown by SSRIs , SNRIs , and tricyclic antidepressants .

Veterinary use [ edit ] Reserpine is used as a long-acting tranquilizer to subdue excitable or difficult horses and has been used illicitly for the sedation of show horses, for-sale horses, and in other circumstances where a "quieter" horse might be desired.

[ 40 ] It is also used in dart guns .

Research [ edit ] Animal model of depression and amotivation [ edit ] Similarly to tetrabenazine , reserpine, via depletion of monoamine neurotransmitters , produces depression -like effects and lack of motivation or fatigue -like symptoms in animals.

[ 41 ] [ 42 ] This can be useful in evaluating new antidepressants and psychostimulant -like agents.

[ 41 ] [ 42 ] Antibacterial effects [ edit ] Reserpine inhibits formation of biofilms by Staphylococcus aureus and inhibits the metabolic activity of bacteria present in biofilms.

[ 43 ] References [ edit ] ^ Tsioufis C, Thomopoulos C (November 2017). "Combination drug treatment in hypertension".

Pharmacological Research .

125 (Pt B): 266– 271.

doi : 10.1016/j.phrs.2017.09.011 .

PMID 28939201 .

S2CID 32904492 .

^ "Reserpine" .

^ James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. (February 2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)".

JAMA .

311 (5): 507– 20.

doi : 10.1001/jama.2013.284427 .

PMID 24352797 .

^ Weir MR (August 2020).

"Reserpine: A New Consideration of and Old Drug for Refractory Hypertension" .

American Journal of Hypertension .

33 (8): 708– 710.

doi : 10.1093/ajh/hpaa069 .

PMC 7402223 .

PMID 32303749 .

^ Barzilay J, Grimm R, Cushman W, Bertoni AG, Basile J (August 2007).

"Getting to goal blood pressure: why reserpine deserves a second look" .

Journal of Clinical Hypertension .

9 (8): 591– 4.

doi : 10.1111/j.1524-6175.2007.07229.x .

PMC 8110058 .

PMID 17673879 .

^ Wang B, Choudhry NK, Gagne JJ, Landon J, Kesselheim AS (March 2015).

"Availability and utilization of cardiovascular fixed-dose combination drugs in the United States" .

American Heart Journal .

169 (3): 379–386.e1.

doi : 10.1016/j.ahj.2014.12.014 .

PMID 25728728 .

^ Forney, Barbara.

Reserpine for Veterinary Use Wedgewood Pharmacy. 2001-2002.

^ Morley JE (May 2014). "Treatment of hypertension in older persons: what is the evidence?".

Drugs & Aging .

31 (5): 331– 7.

doi : 10.1007/s40266-014-0171-7 .

PMID 24668034 .

S2CID 207489850 .

^ Hoenders HJ, Bartels-Velthuis AA, Vollbehr NK, Bruggeman R, Knegtering H, de Jong JT (February 2018).

"Natural Medicines for Psychotic Disorders: A Systematic Review" .

The Journal of Nervous and Mental Disease .

206 (2): 81– 101.

doi : 10.1097/NMD.0000000000000782 .

PMC 5794244 .

PMID 29373456 .

^ Nur S, Adams CE (April 2016).

"Chlorpromazine versus reserpine for schizophrenia" .

The Cochrane Database of Systematic Reviews .

2016 (4): CD012122.

doi : 10.1002/14651858.CD012122.pub2 .

PMC 10350329 .

PMID 27124109 .

^ James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. (February 2014). "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)".

JAMA .

311 (5): 507– 20.

doi : 10.1001/jama.2013.284427 .

PMID 24352797 .

^ Shamon SD, Perez MI (December 2016).

"Blood pressure-lowering efficacy of reserpine for primary hypertension" .

The Cochrane Database of Systematic Reviews .

2016 (12): CD007655.

doi : 10.1002/14651858.CD007655.pub3 .

PMC 6464022 .

PMID 27997978 .

^ "Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group".

JAMA .

242 (23): 2562– 71. December 1979.

doi : 10.1001/jama.242.23.2562 .

PMID 490882 .

full text at OVID ^ "Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg".

JAMA .

202 (11): 1028– 34. December 1967.

doi : 10.1001/jama.202.11.1028 .

PMID 4862069 .

^ "Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group".

JAMA .

265 (24): 3255– 64. June 1991.

doi : 10.1001/jama.265.24.3255 .

PMID 2046107 .

^ ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (December 2002).

"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)" .

JAMA .

288 (23): 2981– 97.

doi : 10.1001/jama.288.23.2981 .

PMID 12479763 .

Archived from the original on November 26, 2009.

^ Shen, Howard (2008).

Illustrated Pharmacology Memory Cards: PharMnemonics . Minireview. p. 11.

ISBN 978-1-59541-101-3 .

^ Thanvi B, Lo N, Robinson T (June 2007).

"Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment" .

Postgraduate Medical Journal .

83 (980): 384– 8.

doi : 10.1136/pgmj.2006.054759 .

PMC 2600052 .

PMID 17551069 .

^ Curb JD, Schneider K, Taylor JO, Maxwell M, Shulman N (March 1988).

"Antihypertensive drug side effects in the Hypertension Detection and Follow-up Program" .

Hypertension .

11 (3 Pt 2): II51-5.

doi : 10.1161/01.hyp.11.3_pt_2.ii51 .

PMID 3350594 .

^ a b AJ Giannini, HR Black. Psychiatric, Psychogenic, and Somatopsychic Disorders Handbook. Garden City, NY. Medical Examination Publishing, 1978. Pg. 233.

ISBN 0-87488-596-5 .

^ Barcelos RC, Benvegnú DM, Boufleur N, Pase C, Teixeira AM, Reckziegel P, et al. (February 2011). "Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats".

Lipids .

46 (2): 143– 9.

doi : 10.1007/s11745-010-3514-0 .

PMID 21161603 .

S2CID 4036935 .

^ kidsgrowth.org Drugs and Other Substances in Breast Milk [ usurped ] Retrieved on June 19, 2009 ^ Pinel JP (2011).

Biopsychology (8th ed.). Boston: Allyn & Bacon. p. 469.

ISBN 978-0-205-83256-9 .

^ Yaffe D, Forrest LR, Schuldiner S (May 2018).

"The ins and outs of vesicular monoamine transporters" .

The Journal of General Physiology .

150 (5): 671– 682.

doi : 10.1085/jgp.201711980 .

PMC 5940252 .

PMID 29666153 .

^ Eiden LE, Weihe E (January 2011).

"VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse" .

Annals of the New York Academy of Sciences .

1216 (1): 86– 98.

Bibcode : 2011NYASA1216...86E .

doi : 10.1111/j.1749-6632.2010.05906.x .

PMC 4183197 .

PMID 21272013 .

^ German CL, Baladi MG, McFadden LM, Hanson GR, Fleckenstein AE (October 2015).

"Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease" .

Pharmacological Reviews .

67 (4): 1005– 24.

doi : 10.1124/pr.114.010397 .

PMC 4630566 .

PMID 26408528 .

^ "Indole Alkaloids" Archived 2011-09-02 at the Wayback Machine Major Types Of Chemical Compounds In Plants & Animals Part II: Phenolic Compounds, Glycosides & Alkaloids.

Wayne's Word: An On-Line Textbook of Natural History. 2005.

^ Ramawat et al, 1999.

Ramawat KG, Sharma R, Suri SS (2007-01-01). Ramawat KG, Merillon JM (eds.).

Medicinal Plants in Biotechnology- Secondary metabolites 2nd edition 2007 . Oxford and IBH, India. pp.

66– 367.

ISBN 978-1-57808-428-9 .

^ Rauwolfia Dorlands Medical Dictionary. Merck Source. 2002.

^ "Reserpine" .

The Columbia Encyclopedia (Sixth ed.). Columbia University Press. 2005. Archived from the original on 2009-02-12.

^ Pills for Mental Illness?

, TIME Magazine , November 8, 1954 ^ a b Nicolaou KC , Sorensen EJ (1996).

Classics in Total Synthesis . Weinheim, Germany: VCH. p.

55 .

ISBN 978-3-527-29284-4 .

^ López-Muñoz F, Bhatara VS, Alamo C, Cuenca E (2004).

"[Historical approach to reserpine discovery and its introduction in psychiatry]" .

Actas Españolas de Psiquiatría .

32 (6): 387– 95.

PMID 15529229 .

^ Everett GM, Toman JE (1959). "Mode of action of Rauwolfia alkaloids and motor activity".

Biol Psychiat .

2 : 75– 81.

^ Govindarajulu M (2021). "Reserpine-Induced Depression and Other Neurotoxicity: A Monoaminergic Hypothesis.". In Agrawal D (ed.).

Medicinal herbs and fungi : neurotoxicity vs. neuroprotection . Singapore: Springer.

ISBN 978-981-334-140-1 .

^ Baumeister AA, Hawkins MF, Uzelac SM (June 2003). "The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis".

Journal of the History of the Neurosciences .

12 (2): 207– 20.

doi : 10.1076/jhin.12.2.207.15535 .

PMID 12953623 .

S2CID 42407412 .

^ Davies DL, Shepherd M (July 1955). "Reserpine in the treatment of anxious and depressed patients".

Lancet .

269 (6881): 117– 20.

doi : 10.1016/s0140-6736(55)92118-8 .

PMID 14392947 .

^ Healy, David (1997).

The Antidepressant Era . Harvard University Press.

ISBN 978-0-674-03958-2 .

^ a b Strawbridge R, Javed RR, Cave J, Jauhar S, Young AH (August 2022).

"The effects of reserpine on depression: A systematic review" .

J Psychopharmacol .

37 (3): 248– 260.

doi : 10.1177/02698811221115762 .

PMC 10076328 .

PMID 36000248 .

S2CID 251765916 .

^ Forney B. Reserpine for veterinary use. Available at http://www.wedgewoodpetrx.com/learning-center/professional-monographs/reserpine-for-veterinary-use.html .

^ a b Stutz PV, Golani LK, Witkin JM (February 2019). "Animal models of fatigue in major depressive disorder".

Physiol Behav .

199 : 300– 305.

doi : 10.1016/j.physbeh.2018.11.042 .

PMID 30513290 .

In a study performed by Sommer et al. (2014), healthy rats treated with the selective dopamine transport (DAT) inhibitor MRZ-9547 (Fig. 1) chose high effort, high reward more often than their untreated matched controls.

^ a b Salamone JD, Yohn SE, López-Cruz L, San Miguel N, Correa M (May 2016).

"Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology" .

Brain .

139 (Pt 5): 1325– 1347.

doi : 10.1093/brain/aww050 .

PMC 5839596 .

PMID 27189581 .

Several recent studies have focused on the effort-related effects of [tetrabenazine (TBZ)]. TBZ inhibits VMAT-2 (i.e. vesicular monoamine transporter type 2, encoded by Slc18a2), which results in reduced vesicular storage and depletion of monoamines. The greatest effects of TBZ at low doses have been reported to be on dopamine in the striatal complex, which is substantially depleted relative to norepinephrine and 5- HT (Pettibone et al., 1984; Tanra et al., 1995). Originally developed as a reserpine-type antipsychotic, TBZ has been approved for use as a treatment for Huntington's disease and other movement disorders, but its major side effects include depressive symptoms (Frank, 2009, 2010; Guay, 2010; Chen et al., 2012). Like reserpine, TBZ has been used in studies involving classical animal models of depression (Preskorn et al., 1984; Kent et al., 1986; Wang et al., 2010). Low doses of TBZ that decreased accumbens dopamine release and dopamine-related signal transduction altered effort-related choice behaviour as assessed by concurrent lever pressing/chow feeding choice procedures (Nunes et al., 2013b; Randall et al., 2014).

^ Parai D, Banerjee M, Dey P, Mukherjee SK (January 2020). "Reserpine attenuates biofilm formation and virulence of Staphylococcus aureus".

Microbial Pathogenesis .

138 103790.

doi : 10.1016/j.micpath.2019.103790 .

PMID 31605761 .

External links [ edit ] NLM Hazardous Substances Databank – Reserpine PubChem Substance Summary: Reserpine National Center for Biotechnology Information.

The Stork Synthesis of (−)-Reserpine v t e Sympatholytic (and closely related) antihypertensives ( C02 ) Sympatholytics (antagonize α-adrenergic vasoconstriction ) Central α 2 -Adrenergic receptor agonists Clonidine Guanabenz Guanfacine Guanoxabenz Methyldopa # Tiamenidine ‡ Adrenergic release inhibitors Bethanidine Bretylium Debrisoquine Guanadrel Guanazodine Guancydine Guanethidine Guanoclor Guanoxan Imidazoline receptor agonists Moxonidine Rilmenidine Tolonidine Ganglion-blocking / nicotinic antagonists Hexamethonium ‡ Mecamylamine Pentolinium Trimethaphan Peripheral Indirect Monoamine oxidase inhibitors Pargyline ‡ VMAT inhibitors Bietaserpine Deserpidine Methoserpidine Reserpine Syrosingopine Tyrosine hydroxylase inhibitors Metirosine Direct α 1 -Adrenergic receptor blockers Doxazosin Ketanserin Indoramin Prazosin Trimazosin Urapidil Non-selective α-adrenergic receptor blockers Phentolamine Other antagonists Serotonin receptor antagonists Ketanserin Lidanserin Endothelin receptor antagonists (for PH Tooltip Pulmonary hypertension ) dual ( Aprocitentan , Bosentan , Macitentan ( +tadalafil ), Riociguat ) selective ( Ambrisentan ( +tadalafil ), Sitaxentan , Sotatercept ) # WHO-EM ‡ Withdrawn from market Clinical trials : † Phase III § Never to phase III v t e Antipsychotics ( N05A ) Typical Butyrophenones : Benperidol Bromperidol Bromperidol decanoate Droperidol Haloperidol # Haloperidol decanoate Moperone Pipamperone Spiperone Timiperone Trifluperidol Diphenylbutylpiperidines : Fluspirilene Penfluridol Pimozide Phenothiazines : Acepromazine Acetophenazine Butaperazine Carphenazine (carfenazine) ‡ Chlorpromazine Cyamemazine Dixyrazine Fluphenazine Fluphenazine decanoate Fluphenazine enanthate Levomepromazine (methotrimeprazine) Mesoridazine Perazine Periciazine Perphenazine BL-1020 Perphenazine decanoate Perphenazine enanthate Piperacetazine Pipotiazine Pipotiazine palmitate Pipotiazine undecylenate Prochlorperazine Promazine Sulforidazine Thiopropazate Thioproperazine Thioridazine Trifluoperazine Triflupromazine Thioxanthenes : Chlorprothixene Clopenthixol Clopenthixol decanoate Flupentixol Flupentixol decanoate Tiotixene (thiothixene) Zuclopenthixol Zuclopenthixol acetate Zuclopenthixol decanoate Disputed Benzamides : Amisulpride Levosulpiride Nemonapride Remoxipride ‡ Sulpiride Sultopride Tiapride Veralipride ‡ Butyrophenones : Melperone Tricyclics : Carpipramine Clocapramine Clorotepine Clotiapine Loxapine Mosapramine Oxyprothepin decanoate Others: Molindone Atypical Benzisoxazole / benzisothiazoles : Iloperidone Lurasidone Paliperidone Paliperidone palmitate Perospirone Risperidone # Ziprasidone Butyrophenones : Lumateperone Phenylpiperazines / quinolinones : Aripiprazole Aripiprazole lauroxil Brilaroxazine † Brexpiprazole Cariprazine Tricyclics : Asenapine Clozapine # Olanzapine ( +samidorphan ) Quetiapine Zotepine Others: Blonanserin Pimavanserin Sertindole Others Monoamine-depleting agents : Oxypertine Reserpine Tetrabenazine Muscarinic agonists : Xanomeline/trospium chloride Others/unknown: Azacyclonol # WHO-EM ‡ Withdrawn from market Clinical trials : † Phase III § Never to phase III v t e Monoamine reuptake inhibitors DAT Tooltip Dopamine transporter ( DRIs Tooltip Dopamine reuptake inhibitors ) Piperazines: DBL-583 GBR-12783 GBR-12935 GBR-13069 GBR-13098 JJC8-088 Nefazodone Vanoxerine Piperidines: 4-Fluoropethidine Benocyclidine (BTCP) Desoxypipradrol Dexmethylphenidate Difemetorex Ethylphenidate HDMP-28 Methylphenidate Pethidine (meperidine) Phencyclidine Pipradrol Serdexmethylphenidate Tenocyclidine Pyrrolidines: Diphenylprolinol MDPV Naphyrone Prolintane Pyrovalerone Tropanes: Altropane Benzatropine (benztropine) Brasofensine CFT Cocaine Dichloropane Difluoropine Etybenzatropine (ethybenztropine) FE-β-CPPIT FP-β-CPPIT Ioflupane ( 123 I) RTI-55 RTI-112 RTI-113 RTI-121 RTI-126 RTI-150 RTI-177 RTI-229 RTI-336 Tesofensine Troparil Tropoxane WF-11 WF-23 WF-31 WF-33 Others: Adrafinil Amifitadine Armodafinil Amfonelic acid Amineptine Ansofaxine BTQ BTS 74,398 Bupropion Chaenomeles speciosa Ciclazindol Dasotraline Desmethylsertraline Desmethylsibutramine (BTS-54354) Diclofensine Didesmethylsibutramine (BTS-54505) Dimethocaine Diphenylpyraline Dizocilpine (MK-801) DOV-102,677 DOV-216,303 Efavirenz Ephenidine Esketamine EXP-561 Fencamfamin Fezolamine Fluorenol GYKI-52895 Hydroxybupropion Indatraline Ketamine Lafadofensine Lefetamine Levophacetoperane Liafensine LR-5182 Manifaxine Mazindol Medifoxamine Mesocarb Metaphit MIN-117 (WF-516) Modafinil Nefopam Nomifensine NS-2359 O-2172 Oroxylin A Perafensine Pridefine Radafaxine Rimcazole Sertraline Sibutramine Solriamfetol Tametraline Tedatioxetine Threohydrobupropion Tripelennamine Venlafaxine NET Tooltip Norepinephrine transporter ( NRIs Tooltip Norepinephrine reuptake inhibitors ) Selective norepinephrine reuptake inhibitors: Amedalin Alseroxylon Ciclazindol Daledalin Edivoxetine Esreboxetine Lortalamine Mazindol Nisoxetine Reboxetine Talopram Talsupram Tandamine Teniloxazine Viloxazine Norepinephrine–dopamine reuptake inhibitors: Amineptine Bupropion Fencamine Fencamfamin Hydroxybupropion Lefetamine Levophacetoperane LR-5182 Manifaxine Methylphenidate Nomifensine O-2172 Radafaxine Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine) CP-39,332 Desvenlafaxine Duloxetine Eclanamine Levomilnacipran McN5652 Milnacipran N-Methyl-PPPA Nafenodone PPPA Tofenacin Venlafaxine Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine Amifitadine Ansofaxine Bicifadine Brasofensine Centanafadine Cocaine Dasotraline Desmethylsertraline Desmethylsibutramine (BTS-54354) Diclofensine Didesmethylsibutramine (BTS-54505) DOV-102677 DOV-216303 EXP-561 Fezolamine HDMP-28 HP-505 Indatraline JNJ-7925476 JZ-IV-10 Lafadofensine Liafensine Mazindol Naphyrone Nefazodone Nefopam NS-2359 Perafensine PRC200 Pridefine SEP-228431 SEP-228432 Sibutramine Tedatioxetine Tesofensine Threohydrobupropion Tropanes (e.g., cocaine ) Tricyclic antidepressants: Amitriptyline Butriptyline Cianopramine Clomipramine Desipramine Dosulepin (dothiepin) Doxepin Imipramine Lofepramine Melitracen Nortriptyline Protriptyline Trimipramine Tetracyclic antidepressants: Amoxapine Maprotiline Mianserin Oxaprotiline Setiptiline Others: Antihistamines (e.g., brompheniramine , chlorphenamine , pheniramine , tripelennamine ) Antipsychotics (e.g., loxapine , ziprasidone ) Arylcyclohexylamines (e.g., ketamine , phencyclidine ) Dopexamine Ephenidine Ginkgo biloba Indeloxazine Nefazodone Opioids (e.g., desmetramadol , methadone , pethidine (meperidine) , tapentadol , tramadol , levorphanol ) SERT Tooltip Serotonin transporter ( SRIs Tooltip Serotonin reuptake inhibitors ) Selective serotonin reuptake inhibitors: 6-Nitroquipazine Alaproclate Centpropazine Cericlamine Citalopram Dapoxetine Desmethylcitalopram Didesmethylcitalopram Escitalopram Femoxetine Fluoxetine Fluvoxamine Indalpine Ifoxetine Norfluoxetine Omiloxetine Panuramine Paroxetine PIM-35 Pirandamine RTI-353 Seproxetine Sertraline Zimelidine Selective serotonin reuptake inhibitors and serotonin receptor modulators: Etoperidone Litoxetine Lubazodone LY-393558 Quipazine SB-649915 TGBA01AD Trazodone Vilazodone Vortioxetine Serotonin–norepinephrine reuptake inhibitors: Atomoxetine (tomoxetine) Bicifadine CP-39332 Desvenlafaxine Duloxetine Eclanamine Levomilnacipran McN5652 Milnacipran N-Methyl-PPPA PPPA Tofenacin Venlafaxine Serotonin–norepinephrine–dopamine reuptake inhibitors: 3,3-Diphenylcyclobutanamine Amifitadine Ansofaxine Bicifadine Brasofensine Centanafadine Cocaine Dasotraline Desmethylsertraline Desmethylsibutramine (BTS-54354) Diclofensine Didesmethylsibutramine (BTS-54505) DOV-102677 DOV-216303 EXP-561 Fezolamine HDMP-28 HP-505 Indatraline JNJ-7925476 JZ-IV-10 Lafadofensine Liafensine Mazindol Naphyrone Nefazodone Nefopam NS-2359 Perafensine PRC200 Pridefine SEP-228431 SEP-228432 Sibutramine Tedatioxetine Tesofensine Threohydrobupropion Tropanes (e.g., cocaine ) Tricyclic antidepressants: Amitriptyline Cianopramine Clomipramine Cyanodothiepin Desipramine Dosulepin (dothiepin) Doxepin Imipramine Lofepramine Nortriptyline Pipofezine Protriptyline Others: A-80426 Amoxapine Antihistamines (e.g., brompheniramine , chlorphenamine , dimenhydrinate , diphenhydramine , mepyramine (pyrilamine) , pheniramine , tripelennamine ) Antipsychotics (e.g., loxapine , ziprasidone ) Arylcyclohexylamines (e.g., 3-MeO-PCP , esketamine , ketamine , methoxetamine , phencyclidine ) Cyclobenzaprine Delucemine Dextromethorphan Dextrorphan Efavirenz Hypidone Medifoxamine Mesembrine Mifepristone MIN-117 (WF-516) N-Me-5-HT Opioids (e.g., dextropropoxyphene , methadone , pethidine (meperidine) , levorphanol , tapentadol , tramadol ) Roxindole VMATs Tooltip Vesicular monoamine transporters Amiodarone Amphetamines (e.g., amphetamine , methamphetamine , MDMA ) APP AZIK Bietaserpine Deserpidine Deutetrabenazine Dihydrotetrabenazine Efavirenz GBR-12935 GZ-793A Ibogaine Ketanserin Lobeline Methoxytetrabenazine Reserpine Rose bengal Tetrabenazine Valbenazine Vanoxerine (GBR-12909) Others Unsorted: Cendifensine DAT enhancers: Luteolin DAT modulators: Agonist-like: SoRI-9804 SoRI-20040 ; Antagonist-like: SoRI-20041 See also: Receptor/signaling modulators • Monoamine releasing agents • Adrenergics • Dopaminergics • Serotonergics • Monoamine metabolism modulators • Monoamine neurotoxins v t e Xenobiotic-sensing receptor modulators CAR Tooltip Constitutive androstane receptor Agonists: 6,7-Dimethylesculetin Amiodarone Artemisinin Benfuracarb Carbamazepine Carvedilol Chlorpromazine Chrysin CITCO Clotrimazole Cyclophosphamide Cypermethrin DHEA ( prasterone ) Efavirenz Ellagic acid Griseofulvin Methoxychlor Mifepristone Nefazodone Nevirapine Nicardipine Octicizer Permethrin Phenobarbital Phenytoin Pregnanedione (5β-dihydroprogesterone) Reserpine TCPOBOP Telmisartan Tolnaftate Troglitazone Valproic acid Antagonists: 3,17β-Estradiol 3α-Androstanol 3α-Androstenol 3β-Androstanol 17-Androstanol AITC Ethinylestradiol Meclizine Nigramide J Okadaic acid PK-11195 S-07662 T-0901317 PXR Tooltip Pregnane X receptor Agonists: 17α-Hydroxypregnenolone 17α-Hydroxyprogesterone Δ 4 -Androstenedione Δ 5 -Androstenediol Δ 5 -Androstenedione AA-861 Allopregnanediol Allopregnanedione (5α-dihydroprogesterone) Allopregnanolone (brexanolone) Alpha-Lipoic acid Ambrisentan AMI-193 Amlodipine besylate Antimycotics Artemisinin Aurothioglucose Bile acids Bithionol Bosentan Bumecaine Cafestol Cephaloridine Cephradine Chlorpromazine Ciglitazone Clindamycin Clofenvinfos Chloroxine Clotrimazole Colforsin Corticosterone Cyclophosphamide Cyproterone acetate Demecolcine Dexamethasone DHEA ( prasterone ) DHEA-S ( prasterone sulfate ) Dibunate sodium Diclazuril Dicloxacillin Dimercaprol Dinaline Docetaxel Docusate calcium Dodecylbenzenesulfonic acid Dronabinol Droxidopa Eburnamonine Ecopipam Enzacamene Epothilone B Erythromycin Famprofazone Febantel Felodipine Fenbendazole Fentanyl Flucloxacillin Fluorometholone Griseofulvin Guggulsterone Haloprogin Hetacillin potassium Hyperforin Hypericum perforatum (St John's wort) Indinavir sulfate Lasalocid sodium Levothyroxine Linolenic acid: α-Linolenic acid and γ-Linolenic acid LOE-908 Loratadine Lovastatin Meclizine Metacycline Methylprednisolone Metyrapone Mevastatin Mifepristone Nafcillin Nicardipine Nicotine Nifedipine Nilvadipine Nisoldipine Norelgestromin Omeprazole Orlistat Oxatomide Paclitaxel Phenobarbital Piperine Plicamycin Prednisolone Pregnanediol Pregnanedione (5β-dihydroprogesterone) Pregnanolone Pregnenolone Pregnenolone 16α-carbonitrile Proadifen Progesterone Quingestrone Reserpine Reverse triiodothyronine Rifampicin Rifaximin Rimexolone Riodipine Ritonavir Simvastatin Sirolimus Spironolactone Spiroxatrine SR-12813 Suberoylanilide Sulfisoxazole Suramin Tacrolimus Tenylidone Terconazole Testosterone isocaproate Tetracycline Thiamylal sodium Thiothixene Thonzonium bromide Tianeptine Troglitazone Troleandomycin Tropanyl 3,5-dimethulbenzoate Zafirlukast Zeranol Antagonists: Ketoconazole Sesamin See also Receptor/signaling modulators v t e Tryptamines Tryptamines 1-Methyl-T 2-HO-NMT 2-Methyl-DET 2, N , N -TMT (2-Me-DMT) 3-IAAR 4-Fluoro-DMT 4-Fluoro-T 5-Bromo-DMT 5-Bromo-T 5-Chloro-DMT 5-Chloro-T 5-CT 5-Ethyl-DMT 5-Fluoro-DET 5-Fluoro-DMT 5-Fluoro-EPT 5-Fluoro-T 5-Me-MiPT 5-MeS-DMT 5-Methyl-DMT 5-Methyl-T 6-Fluoro-DET 6-Fluoro-DMT 6-Fluoro-T 6-HO-DMT 6-HO-T (6-HT) 6-MeO-DMT 6-MeO-T 6-Methyl-T 6,7-DHT 7-Chloro-T 7-HO-T (7-HT) 7-MeO-DMT 7-MeO-T 7-Methyl-DMT 7-Methyl-T Acetryptine (5-AT) Almotriptan Benzotript (4-CB-Trp) BGE Bretisilocin (5-fluoro-MET; GM-2505) Convolutindole A (2,4,6-TBr,1,7-DiMeO-DMT) DALT DAT DBT Desformylflustrabromine DET (T-9) DHT DiPT DMT DPT E-6801 E-6837 EiPT EPT FGIN-127 FGIN-143 Idalopirdine iPALT (ALiPT) Lespedamine (1-MeO-DMT) L-694247 MBT MET MiPT MPT MSBT N -Benzyltryptamine (T-NB, NB-T) N -DEAOP-NET N -DEAOP-NMT NBoc-DMT NET/NETP NiPT NMT NSBT NTBT PALT PiPT Rizatriptan ST-1936 (2-Me-5-Cl-DMT) Sumatriptan TCS-1205 Tryptamine (T; indolylethylamine) Tryptophan (Trp) WAY-181187 Yuremamine Z2876442907 Zolmitriptan 4-Hydroxytryptamines and esters / ethers 1-Methylpsilocin (CMY-16) 4-AcO-DALT 4-AcO-DET (ethacetin, ethylacybin) 4-AcO-DiPT (ipracetin) 4-AcO-DMT (psilacetin; O -acetylpsilocin) 4-AcO-DPT (depracetin) 4-AcO-EPT 4-AcO-MALT 4-AcO-MET (metacetin) 4-AcO-MiPT (mipracetin) 4-AcO-NMT 4-AcO-TMT 4-HO-5-MeO-T 4-HO-DALT (dalocin) 4-HO-DBT 4-HO-DET (ethocin; CZ-74) 4-HO-DPT (deprocin) 4-HO-DSBT 4-HO-EiBT (eibucin) 4-HO-EPT 4-HO-MALT 4-HO-MET (metocin) 4-HO-McPT 4-HO-McPeT 4-HO-MiPT (miprocin) 4-HO-MPT (meprocin) 4-HO-MsBT 4-HO-NALT 4-HO-NiPT 4-HO-PiPT (piprocin) 4-HO-TMT 4-HT (dinorpsilocin) 4-MeO-DiPT 4-MeO-DMT 4-MeO-MiPT 4-MeO-T 4-PrO-DMT 4,5-DHT 4,5-MDO-DMT 4,5-MDO-DiPT Aeruginascin (4-PO-TMT) Baeocystin (4-PO-NMT) EB-002 (EB-373) Ethocybin (4-PO-DET; CEY-19) Iprocin (4-HO-DiPT) Luvesilocin (4-GO-DiPT; RE-104; FT-104) MSP-1014 Norbaeocystin (4-PO-T) Norpsilocin (4-HO-NMT) O-4310 (1-iPrO-6-F-psilocin) Psilocin (4-HO-DMT; CX-59) Psilocybin (4-PO-DMT; CY-39) Psilomethoxin (4-HO-5-MeO-DMT) Psilomethoxybin (4-PO-5-MeO-DMT) RE-109 (4-GO-DMT) 5-Hydroxy- and 5-methoxytryptamines 2-Methyl-5-HT 4-HO-5-MeO-T 4-F-5-MeO-DMT 4,5-DHP-DMT 4,5-DHT 4,5-MDO-DMT 4,5-MDO-DiPT 5-BT 5-Ethoxy-DMT 5-HO-DET 5-HO-DiPT 5-HO-NiPT 5-HO-DPT 5-HTP ( oxitriptan ) 5-MeO-2-TMT 5-MeO-34MPEMT 5-MeO-7, N , N -TMT 5-MeO-DALT 5-MeO-DBT 5-MeO-DET 5-MeO-DiPT 5-MeO-DMT ( N , N , O -TMS; O -methylbufotenine) 5-MeO-DPT 5-MeO-EiPT 5-MeO-EPT 5-MeO-MALT 5-MeO-MET 5-MeO-MiPT 5-MeO-NET 5-MeO-NiPT 5-MeO-NMT ( O , N -DMS) 5-MeO-PiPT 5-MeO-NBpBrT 5-MeO-T (5-MT; mexamine; O -methylserotonin) 5-MeO-T-NBOMe 5-MT-NB3OMe 5-NOT 5,6-DHT 5,6-MDO-DiPT 5,6-MDO-DMT 5,6-MDO-MiPT 5,6-MeO-MiPT 5,7-DHT Arachidonoyl serotonin ASR-3001 (5-MeO-iPALT) BAB Benanserin (BAS; SQ-4788) BGC20-761 Bufotenidine (5-HTQ; N , N , N -TMS) Bufotenin (5-HO-DMT; N , N -DMS; mappine) Bufoviridine (5-SO-DMT) CP-132,484 Cqd 280 Cqd 285 Cqdd 280 Donitriptan EMDT (2-Et-5-MeO-DMT) HIOC Indorenate (TR-3369) Isamide ( N -CA-5-MT) L-741604 MS-245 N -DEAOP-5-MeO-NET N -DEAOP-5-MeO-NMT N -Feruloylserotonin (moschamine) Norbufotenin (5-HO-NMT; NMS) O -Acetylbufotenine (5-AcO-DMT) O -Pivalylbufotenine (5-( t -BuCO)-DMT) Psilomethoxin (4-HO-5-MeO-DMT) Psilomethoxybin (4-PO-5-MeO-DMT) Serotonin (5-HT) N -Acetyltryptamines 2-Iodomelatonin 2-Phenylmelatonin 5-Methoxyluzindole 6-Chloromelatonin 6-Fluoromelatonin 6-Hydroxymelatonin 6-Methoxymelatonin 6,7-Dichloro-2-methylmelatonin α-Methylmelatonin Luzindole Melatonin ( N -Ac- O -Me-serotonin; N -Ac-5-MeO-T) Normelatonin ( N -acetylserotonin; NAS) N -Acetyltryptamine N -Butanoylmelatonin N -Propionylmelatonin Piromelatine TIK-301 (LY-156735) α-Alkyltryptamines 1-Methyl-AMT 2,α-DMT (2-Me-AMT) 4-HO-αMT (MP-14) 4-Methyl-αET 4-Methyl-αMT (MP-809) 5-Chloro-αET (PAL-526) 5-Chloro-αMT (PAL-542) 5-Fluoro-αET (PAL-545) 5-Fluoro-αMT (PAL-212; PAL-544) 5-Methyl-αET 6-Fluoro-αMT 7-Chloro-αMT 7-Me-αET α-Methyltryptophan (αMTP) α, N -DMT ( N -Me-αMT; SKF-7024, Ro 3-1715) α, N , N -TMT (α-Me-DMT; Alpha-N) αET (etryptamine; Monase) αMT (Indopan; IT-290; 3-API; 3-IT) IPAP (α, N -DPT) Soclenicant (BNC-210; Ile–Trp) 5-Hydroxy- and 5-alkoxy-α-alkyltryptamines: 1-Pr-5-MeO-AMT 5-Allyloxy-AMT 5-Ethoxy-αMT 5-iPrO-αMT 5-MeO-αET 5-MeO-αMT (α, O -DMS; Alpha-O) α-Methyl-5-HTP α-Methylmelatonin α-Methylserotonin (5-HO-αMT; α-Me-5-HT) α, N , O -TMS (5-MeO-α, N -DMT) α, N , N , O -TeMS (5-MeO-α, N , N -TMT) AL-37350A (4,5-DHP-αMT) BW-723C86 β-Keto-α-alkyltryptamines: BK-5Br-NM-AMT BK-5Cl-NM-AMT BK-5F-NM-AMT BK-NM-AMT Cyclized tryptamines Barettin Cyclic 3-OHM Ergolines and lysergamides (e.g., LSD ) Harmala alkaloids and β-carbolines (e.g., 5-methoxyharmalan , 6-MeO-THH , 6-methoxyharmalan , 9-Me-BC , β-carboline (norharman) , fenharmane , harmaline , harmalol , harmane , harmine , LY-266,097 , pinoline , tetrahydroharmine , tryptoline ) Iboga alkaloids (e.g., ibogaine , ibogamine , noribogaine , tabernanthine ) Ibogalogs (e.g., catharanthalog , fluorogainalog , ibogainalog , ibogaminalog (DM-506) , LS-22925 , noribogainalog , noribogaminalog , PHA-57378 , PNU-22394 , tabernanthalog ) Imidazolylindoles (e.g., AGH-107 , AGH-192 , AH-494 ) Metralindole Partial ergolines and lysergamides (e.g., NDTDI , RU-27849 , RU-28251 , RU-28306 , FHATHBIN , LY-178210 , Bay R 1531 (LY-197206) , LY-293284 , 10,11-seco-LSD , 10,11-secoergoline (α, N -Pip-T) , CT-5252 ) Pertines (e.g., alpertine , milipertine , oxypertine , solypertine ) Piperidinylethylindoles (e.g., pip-T , indolylethylfentanyl ) Pyrrolidinylethylindoles (e.g., pyr-T , 4-HO-pyr-T , 5-MeO-pyr-T , 4-F-5-MeO-pyr-T ) Pyrrolidinylmethylindoles (e.g., MPMI , 4-HO-MPMI (lucigenol) , 5F-MPMI , 5-MeO-MPMI , CP-122288 , CP-135807 , eletriptan ) Tetrahydrocarbazolamines (e.g., ciclindole , flucindole , frovatriptan , LY-344864 , ramatroban ) Tetrahydropyridinylindoles (e.g., RS134-49 , RU-28253 ) Tetrahydropyrroloquinolines (e.g., bufothionine , O -methylnordehydrobufotenine ) Yohimbans (e.g., yohimbine , rauwolscine , spegatrine , corynanthine , ajmalicine , reserpine , deserpidine , rescinnamine ) Isotryptamines 5-MeO-isoDMT 6-MeO-isoDMT isoAMT (1-API; 1-IT; α-Me-isoT) isoDMT Isotryptamine (isoT) Ro60-0175 VER-3323 Zalsupindole (DLX-001, AAZ-A-154) Cyclized isotryptamines: JRT PNU-181731 Related compounds 2-Azapsilocin 4-Aza-5-MeO-DPT 5-Aza-4-MeO-DiPT 5-HIAA 5-HIAL 5-HITCA 5-MIAL 7-Aza-5-MeO-DiPT α-Carboline γ-Carbolines (pyridoindoles) (e.g., γ-carboline , alosetron , gevotroline , latrepirdine , lurosetron , mebhydrolin , tiflucarbine ) Amedalin Benzindopyrine Benzofurans (e.g., 3-APB , 5-MeO-DiBF , BPAP , 3-F-BPAP , dimemebfe , mebfap , oxa-noribogaine ) Benzothiophenes (e.g., 3-APBT ) Carmoxirole CT-4436 Daledalin Gramine Histamine I-32 IAL IN-399 Indazolethylamines (e.g., AL-34662 , AL-38022A , O -methyl-AL-34662 , VU6067416 , YM-348 ) Indenylethylamines (e.g., C-DMT ) Indolizinylethylamines (e.g., TACT908 (2ZEDMA) , 1ZP2MA , 1Z2MAP1O ) Indolylaminopropanes (e.g., 1-API , 2-API , 4-API , 5-API (5-IT; PAL-571) , 6-API (6-IT) , 7-API ) Iprindole Masupirdine Medmain Molindone Non-tryptamine triptans (e.g., avitriptan , LY-334370 , naratriptan ) Ondansetron Oxazinopyridoindoles (e.g., IHCH-8134 ) Phenethylamines (e.g., phenethylamine , amphetamine ) Piperidinylindoles (e.g., BRL-54443 , LY-334370 , naratriptan , sertindole , SN-22 ) Pirlindole Pyridinylindoles (e.g., tepirindole ) Pyridopyrroloquinoxalines (e.g., IHCH-7113 , IHCH-7079 , IHCH-7086 , lumateperone , deulumateperone , ITI-1549 ) Pyrrolylethylamines (e.g., 2-pyrrolylethylamine (NEA) , 3-pyrrolylethylamine (3-NEA) , 3-pyrrolylpropylamine ) Pyrrolopyridinylethylamines (e.g., WAY-208466 ) Quinolinylethylamines (e.g., mefloquine ) Ro60-0213 Selisistat Tetrahydropyridinylindoles (e.g., EMD-386088 , LY-367265 , RU-24,969 ) Tetrahydropyridinylpyrrolopyridines (e.g., ( R )-69 (3IQ) , ( R )-70 , CP-94253 ) Tetrindole Tipindole Zilpaterol (RU-42173) See also: Phenethylamines Ergolines and lysergamides Psychedelics Authority control databases National Germany United States Israel Other Yale LUX Retrieved from " https://en.wikipedia.org/w/index.php?title=Reserpine&oldid=1302181264 " Categories : Alkaloids found in Rauvolfia Antihypertensive agents Benzoate esters Fetotoxins Heterocyclic compounds with 5 rings Tryptamine alkaloids Indole ethers at the benzene ring Indoloquinolizines Isoquinoline alkaloids Monoamine-depleting agents Plant toxins VMAT inhibitors Depressogens Hidden categories: Webarchive template wayback links Articles with short description Short description is different from Wikidata Drugs with non-standard legal status ECHA InfoCard ID from Wikidata Drugboxes which contain changes to watched fields This page was last edited on 23 July 2025, at 21:49 (UTC) .

Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ;
additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.

, a non-profit organization.

Privacy policy About Wikipedia Disclaimers Contact Wikipedia Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Reserpine 33 languages Add topic

